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Abstract: Advanced theranostic nanomedicine is a multifunctional approach which combines
the diagnosis and effective therapy of diseased tissues. Here, we investigated the preparation,
characterization and in vitro evaluation of theranostic liposomes. As is known, liposome–quantum
dot (L–QD) hybrid vesicles are promising nanoconstructs for cell imaging and liposomal-topotecan
(L-TPT) enhances the efficiency of TPT by providing protection against systemic clearance and
allowing extended time for it to accumulate in tumors. In the present study, hydrophobic CdSe/ZnS
QD and TPT were located in the bilayer membrane and inner core of liposomes, respectively. Dynamic
light scattering (DLS), zeta potential (ζ) measurements and fluorescence/absorption spectroscopy
were performed to determine the vesicle size, charge and spectroscopic properties of the liposomes.
Moreover, drug release was studied under neutral and acidic pH conditions. Fluorescence microscopy
and flow cytometry analysis were used to examine the cellular uptake and intracellular distribution
of the TPT-loaded L–QD formulation. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay was utilized to investigate the in vitro cytotoxicity of the formulations on HeLa cells.
According to the results, the TPT-loaded L–QD hybrid has adequate physicochemical properties and
is a promising multifunctional delivery vehicle which is capable of a simultaneous co-delivery of
therapeutic and diagnostic agents.
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1. Introduction
Nanomedicine is an innovative field with enormous potential for treatment by a combination
of smart nanoparticles with small molecules carrying a wide range of functions [1]. Quantum dots
(QDs) are one of the promising nanoparticles with excellent fluorescence properties, including broad
absorption spectra, narrow emission spectra, high quantum yields, resistance to photobleaching,
and high photochemical stability [2–4]. Due to these characteristics, they have been explored as
fluorescent probes for biomedical applications and are useful in particular for in vivo cell labeling and
imaging [5–8].
Most QDs are typically produced in organic solvents, making them unsuitable for direct use in
biomedical and clinical applications. To overcome this limitation, different surface coatings have been
applied to increase the hydrophilicity of QDs [9,10]. However, surface modifications often lead to
decreases in the QDs’ fluorescence intensity and photostability. In an alternative approach, organic QDs
are inserted into lipid bilayers to enhance their hydrophilicity, stability and biocompatibility [11–14].
Liposomes are self-assembled, spherical lipid-bilayer vesicles that are the most clinically
established nanometer-scale systems [15]. They have the capacity to entrap both lipophilic and
hydrophobic compounds in a lipid membrane and aqueous core, respectively. Thus, the stability,
biocompatibility and solubility of the payloads could be enhanced with the use of several
loading strategies.
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Liposome–QD (L–QD) hybrid vesicles have shown a great potential for theranostic
applications [16]. Tian et al. studied the loading of doxorubicin (DOX) into L–QD hybrid vesicles by the
pH-gradient technique; they characterized these DOX-loaded vesicles using dynamic light scattering
(DLS) and monitored DOX release [17]. Furthermore, Muthu et al. synthesized folic acid-conjugated
theranostic liposomes for the targeted co-delivery of quantum dots and docetaxel [12]. In another
study, apomorphine and QDs were integrated into multifunctional liposomes for brain targeting and
bioimaging and the results showed that these liposomes can be accumulated to a large extent in the
brain [18].
Topotecan (TPT) is a hydrophilic analog of camptothecin. It is a cell-cycle-specific drug and
well established for the treatment of several cancers, including ovarian, small-cell lung and cervical
cancer [19,20]. However, TPT is unstable in physiological conditions and undergoes a pH-dependent
rapid and reversible hydrolysis from a closed lactone ring to the inactive carboxylated form. This
causes the loss of the antitumor activity of the drug. To protect TPT from the hydrolysis, liposome has
been used for encapsulation [21]. Liposomal encapsulation of TPT enhances its efficacy by protecting
it from systemic clearance, allowing greater uptake and extended tissue exposure in solid tumors [22].
In the present study, the aim was to develop multifunctional theranostic liposomes which contain
both the model drug TPT and QDs for cell therapy and imaging. For this purpose, L–QD hybrids were
synthesized by the incorporation of hydrophobic QD within the lipid bilayer. The biocompatibility of
the QDs was increased, retaining its fluorescence characteristics. The pH-gradient technique was used
to encapsulate TPT in the aqueous core of the liposome. Thus, TPT therapeutic activity and QD optical
properties could be successfully integrated into one nanocarrier.
2. Results and Discussion
2.1. Synthesis and Characterization of TPT-Loaded Liposomal Formulations
The proportion of the lipids, distearoylphosphatidylcholine (DSPC) and cholesterol, was chosen
to be 7:3. DSPC was selected as the bulk phospholipid component instead of egg phosphatidylcholine
(EPC) or dimyristoylphosphatidylcholine (DMPC) to increase membrane rigidity, which can also
increase drug retention in liposomes [23,24]. The influence of cholesterol on the stability of the
liposomes has been intensively investigated, which has revealed that cholesterol in sufficient quantity
(≤30%) reduces the leakage of loaded materials from liposome by increasing their stability and
decreasing their permeability [25,26]. Furthermore, cholesterol could enhance the hydrophobicity of the
membrane [27]. Among various synthesis methods, the thin lipid layer hydration method is the most
widely-used and simple method for the preparation of the liposomes. pH-gradient technique, which is
based on pH gradients as a driving force for the accumulation of the weakly-basic molecules into acidic
vesicles, was used to encapsulate TPT into the aqueous core of the liposomes, protecting its active
lactone form until released. The fluorescence spectra of the free drug and liposomal formulations
were measured and indicated that both QD and TPT peaks could be simultaneously observed in the
spectrum (Figure 1). This indicates the coexistence of both molecules in the vesicle. Fluorescence
localizations of the molecules are also photographed in a large liposome (Figure S1).
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Figure 1. The fluorescence spectra of liposome-quantum dot (L–QD) (red), liposome-topotecan 
(L-TPT) (turquoise), L–QD–TPT (orange) and free TPT (green). The excitation wavelength was set at 
450 nm. 
The physicochemical properties of nanoparticles are an important factor in protein interactions 
[28]. It has been reported that nanoparticles having a size less than 150 nm are more suitable for 
permeating through the disorganized and leaky microvasculature of the tumor cells. Besides, their 
more pronounced surface curvature may also reduce the clearance of the particles as a result of 
reduced interaction with the surface receptors on macrophages [29,30]. In this regard, to determine 
hydrodynamic diameters and the surface charge of the liposomes, DLS and ζ-potential analysis were 
carried out (Table 1). The average size of the plain liposomes was measured as ~132 nm. After QD 
entrapment in the lipid bilayer, a ~6 nm increase in liposome size was detected. This could be 
associated with the successful encapsulation of the molecules. TPT encapsulation into L–QD did not 
have an effect on the size (Figure S2). Besides, liposomes were tested for stability upon storage. Over 
2 months, no significant differences in size distribution, ζ-potential as well as PDI occurred at 4 °C. 
The higher surface charge of nanoparticles affects the amount of protein adsorption as well as 
protein corona composition on the surface [31,32]. Studies have signified that liposomes which 
contain highly charged lipids are more susceptible to rapid clearance by the reticuloendothelial 
system (RES). However, neutral and slightly negatively charged nanoparticles have a longer 
circulation lifetime and less accumulation in RES [33–35]. In the present study, ζ-potential 
measurements revealed that the surface potential of the liposomes was slightly negative and 
encapsulations did not show significant alteration in surface charge. TPT encapsulation efficiency 
was calculated around 40%. QD incorporation into the lipid bilayer of liposomes affected just ~4% of 
TPT loading through the lipid membrane. Besides, the obtained polydispersity index values were 
lower than 0.1, confirming the homogeneity of the liposomes (Table 1). Accordingly, the hybrid 
liposomes have better physicochemical properties. 
Table 1. Physicochemical properties and EE% of the liposomes. 
Samples Size (nm) PDI ζ-Potential (mV) EE (%) 
L 131.8 ± 0.8 0.082 −13.6 ± 1.6 - 
L–QD 138.1 ± 0.7 0.014 −7.8 ± 0.1 - 
L–TPT 134.1 ± 1.2 0.073 −10.6 ± 0.1 43.8 
L–QD–TPT 137.1 ± 1.7 0.069 −6.0 ± 0.1 39.5 
The data are presented as the mean ± standard deviation (n = 3). PDI: Polydispersity index; 
ζ-potential: zeta potential; EE: Encapsulation efficiency %. 
2.2. In Vitro Drug Release 
The in vitro drug release profile of L–QD–TPT was investigated by the dialysis method, which 
is one of the most common methods for the determination of drug release from the nanoparticles. 
The analysis was carried out in simulated conditions of normal human tissue (pH 7.4) and a tumor 
microenvironment (pH 5.6) at 37 °C. The acidic environment led to an increased TPT release as 











Figure 1. The fluorescence spectra of liposome-quantum dot (L–QD) (red), liposome-topotecan (L-TPT)
(turquoise), L–QD–TPT (orange) and free TPT (green). The excitation wavelength was set at 450 nm.
The physicochemical properties of n noparticles are important factor in protein
interactions [28]. It has b en reported that nanoparticles having a size less than 150 nm are more
suitable for permeating through the disorganized and leaky microvasculature of the tumor cells.
Besides, their more pronounced surface curvature may also reduce the clearance of the particles as
a result of reduced interaction with the surface receptors on macrophages [29,30]. In this regard,
to determine hydrodynamic diameters and the surface charge of the liposomes, DLS and ζ-potential
analysis were carried out (Table 1). The average size of the plain liposomes was measured as ~132 nm.
After QD entrapment in the lipid bilayer, a ~6 nm increase in liposome size was detected. This could
be associated with the successful encapsulation of the molecules. TPT encapsulation into L–QD did
not have an effect on the size (Figure S2). Be ides, liposom s were tested for stability upon storage.
Over 2 mont s, no signifi ant dif ere ces in size distribution, ζ-potential s well as PDI occurred
at 4 ◦C.
The higher surface charge of nanoparticles affects the amount of protein adsorption as well
as protein corona composition on the surface [31,32]. Studies have signified that liposomes which
contain highly charged lipids are more susceptible to rapid clearance by the reticuloendothelial system
(RES). However, neutral and slightly negatively charged nanoparticles have a longer circulation
lifetime and less accumulation in RES [33–35]. In the present study, ζ-potential measurements
revealed that the surface potential of the liposomes was slightly negative and encapsulations did
not show sig ificant alteration in surfac charge. TPT encapsulation efficienc was calculated
around 40%. QD incorporation into the lipid b layer of liposomes affected just ~4% of TPT loading
through the lipid membrane. Besides, the obtained polydispersity index values were lower than 0.1,
confirming the homogeneity of the liposomes (Table 1). Accordingly, the hybrid liposomes have better
physicochemical properties.
Table 1. Physicochemical properties and EE% of the liposomes.
Samples Size (nm) PDI ζ-Potential (mV) EE (%)
L 131.8 ± 0.8 0.082 −13.6 ± 1.6 -
L–QD 138.1 ± 0.7 0.014 −7.8 ± 0.1 -
L–TPT 134.1 ± 1.2 0.073 −10.6 ± 0.1 43.8
L–QD–TPT 137.1 ± 1.7 0.069 −6.0 ± 0.1 39.5
The data are presented as the mean ± standard deviation (n = 3). PDI: Polydispersity index; ζ-potential:
zeta potential; EE: Encapsulation efficiency %.
2.2. In Vitro Drug Release
The in vitro drug release profile of L–QD–TPT was investigated by the dialysis method, which is
one of the most common methods for the determination of drug release from the nanoparticles.
The analysis was carried out in simulated conditions of normal human tissue (pH 7.4) and a tumor
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microenvironment (pH 5.6) at 37 ◦C. The acidic environment led to an increased TPT release as
compared to neutral conditions (Figure 2). The drug was released with an initial modest burst in the
first 4 h followed by slower rates of release up to 32 h. After 32 h, the release rates of TPT were 39% at
pH 7.4 and 45% at pH 5.6. The higher release rate at an acidic pH can be ascribed to the solubility of
the TPT, which increased with decreasing pH as a result of protonation [36].
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Figure 2. Cumulative drug release profile for L–QD–TPT at mild acidic (pH 5.6) and neutral 
conditions (pH 7.4). Data are presented as mean ± SD (n = 3). 
2.3. Cellular Uptake and Internalization 
Cellular uptake of liposomal formulations was examined via flow cytometry. Cells were treated 
with the samples for 2 h and analyzed using a flow cytometer (BD FACSAria Fusion, Becton, 
Dickinson and Company, Franklin Lakes, NJ, USA). A UV excitation laser (at 400 nm) was used for 
all measurements. Higher fluorescence signals (geometric mean values) were obtained from cells 
treated with the samples compared with untreated control cells. As is clear from Figure 3a, 
intracellular TPT level for L–TPT (3839 a.u.) and L–QD–TPT (4007 a.u.) in HeLa cells was higher than 
that of free TPT (2472 a.u.). This difference can be explained by their different uptake mechanisms. 
Free TPT, a small molecule, is mainly taken into the cells via passive diffusion, whereas liposomes 
enter the cells through endocytosis [37,38]. Besides, QD-loaded liposomes were also successfully 
taken up by the cells (Figure 3b).  
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Figure 3. Cellular uptakes of the conjugates were determined in HeLa cells by flow cytometry. TPT, 
L–TPT, L–QD–TPT (a) (excitation at 400 nm, emission filter FL1 (525/50 nm)); L–QD and L–QD–TPT 
(b) (excitation at 400 nm, emission filter FL2 (610/20 nm)). 
Fluorescence microscopy was used to observe the cellular internalization of the liposomes. The 
images were acquired with separate filter sets. In cells treated with L–QD–TPT, the selected 
fluorescent model drug TPT, which is a topoisomerase-I inhibitor, localized, unsurprisingly, in cell 
nuclei to exert its toxicity [39,40]. The fluorescence from green TPT and blue 
Figure 2. Cumulative drug release profile for L–QD–TPT at mild acidic (pH 5.6) and neutral conditions
(pH 7.4). Data are presented as mean ± SD (n = 3).
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Figure 3. Cellular uptakes of the conjugates were deter ined in HeLa cells by flow cyto etry. TPT,
L–TPT, L–QD–TPT (a) (excitation at 400 nm, emission filter FL1 (525/50 n )); L–QD and L–QD–TPT
(b) (excitation at 400 n , e ission filter FL2 (610/20 n )).
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Fluorescence microscopy was used to observe the cellular internalization of the liposomes. The
images were acquired with separate filter sets. In cells treated with L–QD–TPT, the selected fluorescent
model drug TPT, which is a topoisomerase-I inhibitor, localized, unsurprisingly, in cell nuclei to exert
its toxicity [39,40]. The fluorescence from green TPT and blue 4′,6-diamidino-2-phenylindole (DAPI)
(nuclear stain) matched well (Figure 4a,c). Besides, the Figure 4b and merged picture (Figure 4d)
showed punctate red spots, indicating that QDs had escaped from the endosomes and co-localized
in the cytoplasm and partially in the nucleus. The results are compatible with the outcomes of flow
cytometry analysis as well as with the literature [12]. Dubertret et al. reported the encapsulation
of CdSe/ZnS QDs into phospholipid block-copolymer micelles for in vitro and in vivo imaging.
The QD-micelles injected into individual cells of an early embryo and the internalized QDs were
localized to both the cytosol and nuclear envelope. Besides, QD cytotoxicity was dose dependent [41].
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Figure 4. Fluorescence microscopy of HeLa cells after incubation with L–QD–TPT. Liposomes 
released the payload into the cell (a: TPT; b: QD). Nuclei were stained with 
4′,6-diamidino-2-phenylindole (DAPI) (c). The obtained images were merged into the same picture 
(d). All pictures are in 40× magnification. 
2.4. Cytotoxicity 
The cytotoxicity of the liposomal formulations and free TPT on HeLa cells were determined by 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Only viable cells with 
active metabolism are able to convert MTT into purple-colored formazan; the quantity of the 
formazan is measured by recording the changes in absorbance at 570 nm to 630 nm as the reference 
wavelength. According to the results, L–QD had no toxic effect due to effective shielding of QD by 
lipid bilayer from the surroundings. Similar results were also obtained by Chinnathambi and his 
colleagues. They used phosphoethanolamine(polyethylene glycol)-based phospholipid micelles to 
encapsulate CdSe/ZnS QDs and QD-micelles showed almost no toxicity in the concentration range 
of 0–25 µg/mL in HeLa and A549 cell lines exposed for up to 24 h [42], whereas L–TPT and 
L–QD–TPT showed obvious toxic effects on HeLa cells compared to free TPT for 24 h (p < 0.05, 
Figure 5). This is attributed to the facts that L–TPT and L–QD–TPT were taken up into the cells more 
efficiently (Figure 3) and that the TPT concentration released from liposomes is somewhat higher 
compared to that of free TPT. Hao et al. also found similar results regarding the enhancement of the 
antiproliferation ability of TPT with liposomal encapsulation [43]. 
Figure 4. Fluorescence microscopy of HeLa cells after incubation with L–QD–TPT. Liposomes released
the payload into the cell (a: TPT; b: QD). Nuclei were stained with 4′,6-diamidino-2-phenylindole
(DAPI) (c). The obtained images were merged into the same picture (d). All pictures are in
40×magnification.
2.4. Cytotoxicity
The cytotoxicity of the liposomal formulations and free TPT on HeLa cells were determined by
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Only viable cells with
active metabolism are able to convert MTT into purple-colored formazan; the quantity of the formazan
is measured by recording the changes in absorbance at 570 nm to 630 nm as the reference wavelength.
According to the results, L–QD had no toxic effect due to effective shielding of QD by lipid bilayer from
the surroundings. Similar results were also obtained by Chinnathambi and his colleagues. They used
phosphoethanolamine(polyethylene glycol)-based phospholipid micelles to encapsulate CdSe/ZnS
QDs and QD-micelles showed almost no toxicity in the concentration range of 0–25 µg/mL in HeLa
and A549 cell lines exposed for up to 24 h [42], whereas L–TPT and L–QD–TPT showed obvious toxic
effects on HeLa cells compared to free TPT for 24 h (p < 0.05, Figure 5). This is attributed to the facts
that L–TPT and L–QD–TPT were taken up into the cells more efficiently (Figure 3) and that the TPT
concentration released from liposomes is somewhat higher compared to that of free TPT. Hao et al. also
Int. J. Mol. Sci. 2017, 18, 1415 6 of 11
found similar results regarding the enhancement of the antiproliferation ability of TPT with liposomal
encapsulation [43].
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3. aterials and ethods
3.1. Materials
The 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 4,6-diamino-2-
phenylindol (DAPI), Dulbecco’s modified eagle medium (DMEM) and cholesterol were ordered
from Sigma Aldrich (Munich, Germany). CdSe/ZnS core/shell hydrophobic quantum dots (QDs) with
an overall diameter of ~5 nm were obtained from PlasmaChem GmbH (Berlin, Germany). Topotecan
and 1,2-distearoyl-sn-glycero-3-PC (DSPC) were purchased from Cayman Chemical (Ann Arbor, MI,
USA).
3.2. Synthesis of L–QD Hybrids
L–QD hybrids were synthesized by the thin film hydration method [44]. Briefly, DSPC:Cholesterol
(7:3 molar ratio) and 30 µg/mL CdSe/ZnS QD (λem = 600 nm) solutions in chloroform were added
into a round bottom flask. The mixture was placed in an evaporator to obtain a thin QD-containing
lipid film and exposed to N2 gas for just a few minutes to remove the residual of organic solvents.
The dried film was hydrated with 250 mM ammonium sulphate (pH 6.5) at 60 ◦C, which is above
the gel–liquid melting transition temperature (Tm) of all lipids. Small unilamellar vesicles (SUVs)
were prepared starting from multilamellar vesicles (MLVs) by using sonication and extruding through
0.4 µm and 0.1 µm pore size polycarbonate membranes in mini-extruder set (Avanti Polar Lipids,
Alabaster, AL, USA). Afterward, liposomes were centrifuged at 11,000 rpm for 15 min to remove the
excess non-incorporated quantum dots [45].
3.3. Encapsulation of Model Drug TPT
L–QD hybrids were loaded actively with TPT using the pH-gradient technique [46]. The obtained
lipid-QD dried thin film was hydrated with 250 mM ammonium sulphate (pH 6.5) at 60 ◦C.
After sonication, dialyzed against 10 mM HEPES buffered saline (HBS, pH 7.5) to adjust the exterior
pH value of the liposomes as in physiological conditions. The suspension was then mixed with
0.1 mM TPT solution (in 0.9% NaCl) followed by 1 h incubation in a 60 ◦C water bath. L–QD–TPT was
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extruded through 0.4 µm and 0.1 µm polycarbonate membranes, respectively. Finally, liposomes were
centrifuged at 11,000 rpm for 15 min to remove the excess non-incorporated molecules.
3.4. Encapsulation Efficiency
The percent of encapsulation efficiency (EE%) of TPT was calculated according to the following
Equation (1):
EE%TPT = (Wen/ Wtotal) × 100% (1)
where Wen is the analyzed weight of the drug encapsulated in liposome and Wtotal is the initial
amount of the drug [47]. It was determined after lysis of the liposomes by diluting purified
liposomes in acidic methanol (1% trifluoroacetic acid in methanol). Calibration curves were established
with known concentrations of free TPT by fluorescence emission measurements at 530 nm using
a fluorospectrometer (NanoDrop 3300, Thermo Fisher Scientific Inc., Waltham, MA, USA).
3.5. Characterization
The fluorescence spectra of the free drug and liposomal formulations were measured using a
spectrofluorometer. The localizations of QD and TPT in a large liposome were photographed using an
Olympus BX41 fluorescence microscope (Shinjuku, Tokyo, Japan) equipped with an Olympus SC30
camera and processed by Image J software [48].
The particle size distribution and zeta potential (ζ) of the liposomes were determined by Zetasizer
Nano-ZS (Malvern Instruments, Malvern, UK). The polydispersity index (PDI) was reported as a
measure of the width of size distribution. The samples were diluted at the ratio of 1:100 (v/v) with
ddH2O and equilibrated for 3 min before the measurements. Measurements were taken three times
at room temperature. To test their stability, liposomal formulations were stored at 4 ◦C in the dark.
After 2 months, their size distribution, ζ-potential and PDI were analyzed.
3.6. In Vitro Drug Release
The dialysis technique was used for drug release experiments. L–QD–TPT was prepared and
transferred into a pre-washed dialysis tubing (Slide-A-Lyzer MINI Dialysis Devices, 10K MWCO,
Thermo Fisher Scientific Inc., Waltham, MA, USA). The tubing was immersed in 10 mL of the Phosphate
buffered saline (PBS) buffer (pH 5.6 and 7.4), placed in an incubator at 37 ◦C and stirred at 100 rpm.
At specific time intervals, 0.5 mL samples were removed from the release medium and replaced
with the same volume of fresh buffer. The amount of released TPT was calculated according to the
calibration curves. They were established with a known concentration of free TPT by fluorescence
emission measurements at 530 nm using a spectrofluorometer.
3.7. Cell Culture
Human cervical cancer cell (HeLa cell) line was provided from the German Collection of
Microorganisms and Cell Cultures (DSMZ) (Braunschweig, Germany). Cells were grown in DMEM
containing 10% fetal calf serum (FCS) and 1.0% penicillin/streptomycin (P/S). HeLa cells were
cultivated in this medium and incubated with samples and reagents at 37 ◦C in a humidified
environment with 5.0% CO2.
3.8. Cytotoxicity
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays were used to
determine the cytotoxicity of the liposomal formulations. Cells (8 × 103) were seeded out in 96-well
tissue plates (Sarstedt, Newton, MA, USA) in a volume of 200 µL and cultivated for three days.
After this cultivation period, cells were washed once with PBS and treated with L–QD, L–TPT,
L–QD–TPT and free TPT for 24 h. The equivalent concentration of free TPT was used in liposomal
formulations. The samples were then removed and the cells were incubated in 110 µL/well 10% MTT
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solution (5.0 mg/mL in PBS) in the medium for 4 h. During this incubation time, formazan complex
was produced by the cells. A 100 µL SDS solution (1.0 g SDS in 10 mL 0.01 M HCl) was added to each
well to release the purple-colored salt from the cells. After 24 h of incubation, UV-Vis absorption was
measured at 570 nm to 630 nm as the reference wavelength using a microplate reader (Epoch BioTek,
Winooski, VT, USA).
3.9. Cellular Uptake and Internalization
The cellular uptake of TPT and liposomal formulations by HeLa cells was examined through
flow cytometry. Cells (5 × 105) were collected and incubated with the samples for 2 h, followed by
washing two times with PBS. Just before the analysis, cells were resuspended in 500 µL of PBS and
then analyzed in a BD FACSAria Fusion flow cytometer (Becton, Dickinson and Company, Franklin
Lakes, NJ, USA). At least 20,000 gated events were observed in total and living cells were gated in a
dot plot of forward versus side scatter signals. The dot plot and histogram data were analyzed by
Flowing Software 2 [49].
Cellular internalization of L–QD–TPT was determined via fluorescence microscopy studies. HeLa
cells were cultivated for 2 days on the chamber slides (8-well µ slides purchased from ibidi GmbH,
Munich, Germany) in a volume of 200 µL of the medium. Samples were diluted with the medium and
then added to the cells. The cells were incubated for 4 h at 37 ◦C and washed twice in PBS. Afterwards,
100 µL DAPI solution (1.0 mg/mL) was added to the cells, which were then incubated for 15 min. Cells
were washed with PBS once following DAPI staining. Images were taken using an Olympus BX41
fluorescence microscope equipped with an Olympus SC30 camera and processed by Image J software.
3.10. Statistical Analysis
Statistical data analysis was performed using the Student’s t-test. The difference between two
groups was considered to be significant when the p-value was less than 0.05.
4. Conclusions
The theranostic liposomes, with a mean size of about 135 nm, were developed for the co-delivery
of imaging and therapeutic agents. Both hydrophobic QD and hydrophilic TPT were encapsulated
into liposomes by thin film hydration and pH-gradient methods, respectively. Thus, bioavailability of
a poorly water-soluble molecule was enhanced and moreover, the therapeutic efficacy and stability of
the drug were improved. The well-characterized liposomal TPT formulations showed significantly
higher cellular uptake as well as higher cytotoxicity than free TPT. QD internalization into cells was
achieved and enabled simultaneous imaging. This liposome–nanoparticle hybrid system might offer
new opportunities for the development of novel co-delivery platforms.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/7/1415/s1.
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